CA-certified Chemical and Pharmaceuticals project reports delivered in 24-48 hours—Sharda Associates has helped 45,500+ businesses across India get bank-ready, including chemical and pharma units where regulatory licensing and product category decide the entire cost and timeline structure, built around your actual product category and licensing stage.
Get Your Report
₹8,999
Starting Price (DPR)
CA-Certified
Consultancy
45,500+
Reports Delivered
What Should Be in Your Chemical or Pharma Project Report?
If you’re setting up a chemical or pharma unit, this report is what shows the bank your product category, manufacturing setup, and regulatory status—and proves your projected sales can realistically repay the loan. It starts by defining the segment you’re entering: bulk chemicals, specialty/fine chemicals, formulations (tablets/capsules/syrups), or APIs, along with the manufacturing process and quality systems that segment demands.
From there, it breaks down machinery cost across reaction vessels, distillation/purification, or formulation and packing lines, depending on your segment, and lays out your raw material sourcing plan, since many chemical inputs are imported and price-volatile. It fixes a realistic production capacity and builds the revenue plan around your actual buyer type—domestic bulk drug companies, formulation manufacturers, institutional supply, or export.
Which Segment Should the Report Be Built Around?
This decision changes your entire licensing timeline and capital structure, so it’s worth settling before the report is drafte
| Segment | Regulatory Body | Approx. Investment Range* | Best Suited For |
|---|---|---|---|
| Bulk / Specialty Chemicals | State Pollution Control Board, Factory License | ₹50 lakh–5 crore | Industrial chemical supply, lower licensing complexity |
| Formulations (Tablets / Syrups) | State FDA, Schedule M / GMP Compliance | ₹1–8 crore | Domestic pharma market, faster licensing than API |
| API / Bulk Drug Manufacturing | CDSCO, WHO-GMP for Export | ₹5–25 crore | Higher margin, longer licensing timeline, export potential |
- Formulation units generally have a faster licensing path than API manufacturing, making them a more common entry point for first-time pharma entrepreneurs
- API manufacturing needs WHO-GMP certification for meaningful export revenue, this needs to be reflected honestly in your timeline, not assumed as immediate
What Loan Type Actually Fits This Kind of Project?
Working Capital / Cash Credit
MSME Schemes (CGTMSE, PMEGP)
relevant where a meaningful share of revenue is projected from export markets, given different documentation and repayment terms.
What You'll Need Before You Apply
financial side
Bank statements (6-12 months) and existing loan details fall under the financial side
Regulatory status matters most here
State FDA/CDSCO license or application status, Pollution Control Board consent, and GMP/WHO-GMP certification status
Project side
Get machinery quotations, process flow diagram and proof of product/segment classification ready on the project
Land documentation
ownership/lease papers, land use permission, and building plan approval
And on the promoter side:
And on the promoter side: PAN, Aadhaar, address proof, and last 2-3 years' financial statements
What Gets the Bank's Attention First?
1
Is your product segment correctly classified and does your licensing plan match it?
2
Is your revenue ramp-up realistic given actual licensing and certification timelines?
3
Do you have a genuine buyer pathway (institutional, distributor, export), or just an assumption?
4
Is effluent treatment and pollution compliance status clear?
5
Is your working capital sized for real import lead times and institutional payment cycles?
6
Is machinery and infrastructure cost backed by actual vendor quotations?
7
Does the promoter or technical team have relevant pharma or chemical manufacturing background?
Who Is This Report Actually For?
1
First-time entrepreneurs entering formulation manufacturing, typically a faster licensing path than API
2
Existing manufacturers expanding into a new segment or adding API capabilit
3
Promoters with a pharmacy or chemical engineering background entering manufacturing
4
Partnership firms or private limited companies targeting institutional or export sales
5
Applicants eligible for PLI or MSME schemes specific to pharma and chemicals
How Sharda Associates Actually Builds Your Report
- We confirm your product segment and realistic licensing timeline first, then structure cost and revenue around that, not an assumed fast-track scenario
- Working capital is sized around actual institutional payment cycles and import lead times, since this is where most applications in this sector get flagged
- GMP/WHO-GMP and pollution compliance costs are built in as real project cost line items from the start, so the bank sees a complete, credible picture
Frequently Asked Questions
A document covering product segment, machinery cost, regulatory status, and financial projections, used by banks and NBFCs to assess loan eligibility.
Yes, bulk chemicals, formulations, and API manufacturing differ hugely in licensing complexity, cost, and timeline, and the report is built entirely around the actual segment chosen.
Anywhere from a few months for lower-complexity chemical units to 12-18 months for API/WHO-GMP certification, and the report's revenue timeline reflects this realistically.
Not always mandatory for the loan itself, but most institutional buyers require it, so it's included as a project cost even if not yet completed.
Yes, import lead time, customs duty, and currency risk are factored into both cost structure and working capital cycle.
Promoter KYC, land documents, machinery quotations, segment classification proof, and FDA/CDSCO/pollution status wherever already available.
Yes, where the category qualifies under the Production Linked Incentive scheme, the report is structured to support both.
No, it presents a realistic, credible case to the lender, actual approval still depends on the bank's internal credit policy and your overall financial profile.